Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 15/20 | 0.45 |
| ▸ | NMBR | P28336 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2040840 | 0.88 | SIRT2 (0.50) | SIRT2 | |
| SCHEMBL2052215 | 0.85 | SIRT2 (0.46) | SIRT2NMBR | |
| SCHEMBL28803224 | 0.79 | SIRT2 (0.49) | SIRT2NMBRENPP2CYP11B1CYP11B2 | |
| SCHEMBL877052 | 0.76 | SIRT2 (0.46) | SIRT2NMBRENPP2CYP11B1CYP11B2 | |
| SCHEMBL27885485 | 0.75 | SIRT2 (0.50) | SIRT2NMBR | |
| SCHEMBL19208762 | 0.75 | SIRT2 (0.51) | SIRT2NMBR | |
| SCHEMBL18991426 | 0.74 | SIRT2 (0.47) | SIRT2NMBR | |
| SCHEMBL1342 | 0.74 | SIRT2 (0.45) | SIRT2NMBRENPP2CYP11B1CYP11B2 | |
| SCHEMBL877785 | 0.74 | SIRT2 (0.46) | SIRT2NMBRCYP11B1CYP11B2 | |
| Acetic Acid SCHEMBL7659782 | 0.74 | SIRT2 (0.47) | SIRT2NMBRENPP2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3000482-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2021-04-21 | — | — | EP | disclosed |
| CN-104311657-B | Double acylated GLP-1 derivatives | 诺沃—诺迪斯克有限公司 | 2020-12-08 | — | — | CN | disclosed |
| CN-111560060-A | Double acylated GLP-1 derivatives | 诺沃—诺迪斯克有限公司 | 2020-08-21 | — | — | CN | disclosed |
| CN-104327182-B | Double acylated GLP-1 derivatives | 诺沃—诺迪斯克有限公司 | 2020-04-17 | — | — | CN | disclosed |
| EP-2513141-B1 | GLP-1 ANALOGUES AND DERIVATIVES | NOVO NORDISK AS (DK) | 2017-03-01 | — | — | EP | disclosed |
| US-9556250-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2017-01-31 | — | — | US | disclosed |
| EP-3000482-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | Novo Nordisk A/S (DK) | 2016-03-30 | — | — | EP | disclosed |
| EP-2513140-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2015-11-04 | — | — | EP | disclosed |
| US-8815802-B2 | GLP-1 analogues and derivatives | NOVO NORDISK A/S (DK) | 2014-08-26 | — | — | US | disclosed |
| US-20140179899-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2014-06-26 | — | — | US | disclosed |
| US-8648041-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2014-02-11 | — | — | US | disclosed |
| US-20130053311-A1 | GLP-1 ANALOGUES AND DERIVATIVES | NOVO NORDISK A/S (DK) | 2013-02-28 | — | — | US | disclosed |
| US-20120329711-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS | NORDISK A/S (DK) | 2012-12-27 | — | — | US | disclosed |
| US-20110166321-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166321-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | GLP1R, IAPP, GCG | SIRT2 527/4885NMBR 3828/4885SORT1 2201/4885 |
| US-20130053311-A1 | GLP-1 ANALOGUES AND DERIVATIVES | GLP1R, IAPP, SLC5A1 | SIRT2 1010/4885NMBR 1610/4885SORT1 3680/4885 |
| US-20140179899-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | GLP1R, GCG, DPP7 | SIRT2 233/4885NMBR 2784/4885SORT1 612/4885 |
| US-20120329711-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS | GLP1R, GIPR, GCGR | SIRT2 2991/4885NMBR 1600/4885SORT1 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.